CIK 0001159036 · Large accelerated filer
HALOZYME THERAPEUTICS, INC.
Sign in to watch- Ticker
- HALO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880488686
- Phone
- (858) 794-8889
- Business address
- 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,884,955
- in 5 filings, $19.9M under 10b5-1 plans
Net −$19,884,955. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Posard Matthew L. Director | Sale 10b5-1 | −730 | $107.17 | $78K | 58,109 |
| 2026-10-01 | Posard Matthew L. Director | Sale 10b5-1 | −3,300 | $108.45 | $358K | 54,809 |
| 2026-10-01 | Posard Matthew L. Director | Sale 10b5-1 | −1,100 | $109.57 | $121K | 53,709 |
| 2026-10-01 | Posard Matthew L. Director | Sale 10b5-1 | −100 | $110.04 | $11K | 53,609 |
| 2026-09-16 | Posard Matthew L. Director | Sale 10b5-1 | −3,100 | $106.13 | $329K | 74,735 |
| 2026-09-16 | Posard Matthew L. Director | Sale 10b5-1 | −3,000 | $106.83 | $320K | 71,735 |
| 2026-09-16 | Posard Matthew L. Director | Sale 10b5-1 | −8,896 | $108.04 | $961K | 62,839 |
| 2026-09-16 | Posard Matthew L. Director | Sale 10b5-1 | −4,000 | $108.99 | $436K | 58,839 |
| 2026-09-11 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-09-11 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −15,492 | $107.15 | $1.7M | 772,288 |
| 2026-09-11 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −4,508 | $107.55 | $485K | 767,780 |
| 2026-09-11 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $18.41 | $368K | 81,552 |
| 2026-09-10 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-09-10 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −14,588 | $107.01 | $1.6M | 773,192 |
| 2026-09-10 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −5,412 | $107.58 | $582K | 767,780 |
| 2026-09-10 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $18.41 | $368K | 101,552 |
| 2026-09-09 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-09-09 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −13,304 | $107.22 | $1.4M | 774,476 |
| 2026-09-09 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −6,596 | $107.82 | $711K | 767,880 |
| 2026-09-09 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −100 | $108.67 | $11K | 767,780 |
Page 2 of 26 · 513 trades